Novel HDAC6 inhibitor 2

Novel HDAC6 inhibitor 2 is a preclinical small molecule inhibitor of histone deacetylase 6 (HDAC6) identified through a high-throughput screen of 9,600 compounds. Developed by researchers at Case Western Reserve University and University Hospitals - Seidman Cancer Center, the compound is designed to treat hematologic malignancies such as multiple myeloma and lymphoma. Its mechanism of action involves the selective inhibition of HDAC6, which subsequently increases intracellular proteasomal activity. This enhancement leads to the increased generation and presentation of antigenic MHC-class I peptides on the tumor cell surface, thereby boosting recognition and lysis by CD8+ cytotoxic T lymphocytes (CTLs). In preclinical studies, it has demonstrated superior potency and more rapid activation of proteasomal activity compared to established HDAC6 inhibitors like ricolinostat (ACY-1215) and tubastatin-A, while maintaining low cytotoxicity.